Sunday, April 14

Add-On Fruquintinib Delays Progression in Gastric Cancer


In clients with stomach or gastroesophageal cancer who have actually advanced on frontline chemotherapy, including fruquintinib to paclitaxel substantially postpones development however stops working to enhance general survival, brand-new stage 3 information revealed.


  • Second-line treatment choices for clients with stomach or gastroesophageal cancer are restricted to chemotherapy with or without ramucirumab, leaving an immediate requirement for alternative treatment choices.
  • The stage 3 double-blind, placebo-controlled FRUTIGA trial registered 703 clients with stomach or gastroesophageal cancer who had actually advanced on fluoropyrimidine- or platinum-containing chemotherapy.
  • Clients were arbitrarily appointed 1:1 to get fruquintinib with paclitaxel or placebo with paclitaxel up until illness development. Nearly all clients were Asian.
  • Main endpoints were progression-free survival (PFS) and total survival; secondary endpoints were total action rate, illness control rate, period of reaction, security, and lifestyle.


  • Clients in the fruquintinib group had substantially much better PFS than those in the placebo group (5.6 months vs 2.7 months; danger ratio [HR]0.57). Practically 2 times as lots of clients getting fruquintinib had a general action rate (42.5% vs 22.4%).
  • Clients getting fruquintinib did not show a substantial general survival advantage over the mean research study follow-up of 31.7 months. Average total survival was 1.2 months longer in the fruquintinib group (9.6 months vs 8.4 months; HR, 0.96; P =.6064).
  • When taking a look at a subgroup of clients with lymph node metastases and non-diffuse histology, those getting fruquintinib did reveal a small however substantial total survival advantage with an average total survival distinction of 1.7 months (9.6 vs 7.9 months; HR, 0.77; P =.0233). The scientists likewise kept in mind a small however substantial general survival advantage in the fruquintinib group after changing for subsequent anticancer treatment and standard qualities (HR variety, 0.79-0.83; P variety =.0105 -.0350).
  • Treatment-emergent grade 3 or greater unfavorable occasion rates were 86.9% in the fruquintinib arm vs 63.3 % in the placebo group. The most typical grade 3 plus negative occasions were neutropenia (60.0% vs 36.4%), leukopenia (42.9% vs 23.5%), and anemia (11.7% vs 10.6%).


“Fruquintinib plus paclitaxel might be an appealing second-line treatment choice for clients with innovative gastric/gastroesophageal adenocarcinoma who have actually stopped working fluoropyrimidine or platinum chemotherapy,” lead research study author Rui-hua Xu, MD, PhD, from Sun Yat-sen University Cancer Center in Guangzhou, China, stated in a news release.


This research study, led by Rui-Hua Xu, MD, PhD, Sun Yat-sen University Cancer Center, existed at the ASCO Plenary Series on February 6, 2024, and at the same time released in the Journal of Clinical Oncology


Nearly all clients registered were Asians, restricting generalizability. An active comparator was not utilized. Details on subsequent treatments, growth biology, and biomarkers was not offered.


This research study was sponsored by Hutchison Medipharma Limited. Xu stated getting consulting/advisory charges beyond this work.

ยป …
Find out more